<?xml version="1.0" encoding="UTF-8"?>
<ref id="cam41388-bib-0003">
 <label>3</label>
 <mixed-citation publication-type="journal" id="cam41388-cit-0003">
  <string-name>
   <surname>Aapro</surname>, 
   <given-names>M. S.</given-names>
  </string-name>, 
  <string-name>
   <given-names>J.</given-names>
   <surname>Bohlius</surname>
  </string-name>, 
  <string-name>
   <given-names>D. A.</given-names>
   <surname>Cameron</surname>
  </string-name>, 
  <string-name>
   <given-names>L.</given-names>
   <surname>Dal Lago</surname>
  </string-name>, 
  <string-name>
   <given-names>J. P.</given-names>
   <surname>Donnelly</surname>
  </string-name>, 
  <string-name>
   <given-names>N.</given-names>
   <surname>Kearney</surname>
  </string-name>, et al. 
  <year>2011</year>
  <article-title>2010 update of EORTC guidelines for the use of granulocyte‐colony stimulating factor to reduce the incidence of chemotherapy‐induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours</article-title>. 
  <source>Eur. J. Cancer</source>
  <volume>47</volume>:
  <fpage>8</fpage>–
  <lpage>32</lpage>.
  <pub-id pub-id-type="pmid">21095116</pub-id>
 </mixed-citation>
</ref>
